Belite Bio Inc
NASDAQ:BLTE

Watchlist Manager
Belite Bio Inc Logo
Belite Bio Inc
NASDAQ:BLTE
Watchlist
Price: 159.27 USD -0.43% Market Closed
Market Cap: 5.6B USD

Belite Bio Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Belite Bio Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Belite Bio Inc
NASDAQ:BLTE
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Revenue
$92.1B
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$48B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$62.8B
CAGR 3-Years
-14%
CAGR 5-Years
9%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Revenue
$64.2B
CAGR 3-Years
3%
CAGR 5-Years
13%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Revenue
$59.4B
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
12%
No Stocks Found

Belite Bio Inc
Glance View

Market Cap
5.1B USD
Industry
Pharmaceuticals

Belite Bio Inc., a biopharmaceutical company based in San Diego, operates with a keen focus on the development of innovative therapies aimed at treating eye diseases and related metabolic disorders. At the heart of their strategic pursuits is the compound LBS-008, aimed at tackling Stargardt disease and dry age-related macular degeneration (AMD). Stargardt disease, a hereditary eye condition leading to progressive vision loss, represents a significant unmet medical need that Belite Bio endeavors to address. The company works at the intersection of science and hope, blending rigorous research efforts with a deep commitment to improving patients' lives. Utilizing a methodology rooted in targeting retinol binding protein 4 (RBP4), Belite Bio seeks to mitigate the toxic accumulation of vitamin A byproducts that are primarily responsible for these vision impairments. Belite Bio generates revenue mainly through strategic partnerships and licensing agreements, aligning with larger pharmaceutical companies to advance the latter stages of clinical development and commercialization of their drugs. This business model allows Belite Bio to leverage the infrastructure and market reach of its partners, maximizing the therapeutic potential and market penetration of their findings. Additionally, the company is proactive in pursuing grants and funding to fuel its research and development pipeline, ensuring that resources are channeled towards expediting the creation of their solutions. Through this hybrid economic strategy—balancing internal innovation with external collaboration—Belite Bio capitalizes on its scientific prowess, aiming to convert its pipeline products into market successes that address critical gaps in the treatment landscape of ocular disorders.

BLTE Intrinsic Value
Not Available

See Also

What is Belite Bio Inc's Revenue?
Revenue
0 USD

Based on the financial report for Dec 31, 2024, Belite Bio Inc's Revenue amounts to 0 USD.

Back to Top